Information Technology Services
Compare Stocks
5 / 10Stock Comparison
NYAX vs ACMR vs ICHR vs IIIV vs MKSI
Revenue, margins, valuation, and 5-year total return — side by side.
Semiconductors
Semiconductors
Software - Infrastructure
Hardware, Equipment & Parts
NYAX vs ACMR vs ICHR vs IIIV vs MKSI — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Information Technology Services | Semiconductors | Semiconductors | Software - Infrastructure | Hardware, Equipment & Parts |
| Market Cap | $2.67B | $3.92B | $2.47B | $506M | $20.25B |
| Revenue (TTM) | $404M | $901M | $959M | $223M | $4.07B |
| Net Income (TTM) | $36M | $94M | $-51M | $16M | $327M |
| Gross Margin | 46.3% | 44.4% | 11.3% | 60.4% | 45.2% |
| Operating Margin | 9.7% | 12.1% | -3.8% | 0.8% | 14.8% |
| Forward P/E | 81.5x | 29.7x | 62.2x | 20.3x | 30.4x |
| Total Debt | $338M | $303M | $186M | $8M | $4.69B |
| Cash & Equiv. | $412M | $766M | $98M | $67M | $675M |
NYAX vs ACMR vs ICHR vs IIIV vs MKSI — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 22 | May 26 | Return |
|---|---|---|---|
| Nayax Ltd. (NYAX) | 100 | 305.9 | +205.9% |
| ACM Research, Inc. (ACMR) | 100 | 475.1 | +375.1% |
| Ichor Holdings, Ltd. (ICHR) | 100 | 294.2 | +194.2% |
| i3 Verticals, Inc. (IIIV) | 100 | 114.4 | +14.4% |
| MKS Inc. (MKSI) | 100 | 364.0 | +264.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NYAX vs ACMR vs ICHR vs IIIV vs MKSI
Each card shows where this stock fits in a portfolio — not just who wins on paper.
NYAX carries the broadest edge in this set and is the clearest fit for growth exposure and sleep-well-at-night.
- Rev growth 38.0%, EPS growth 7.4%, 3Y rev CAGR 35.7%
- Lower volatility, beta 0.71, current ratio 2.26x
- 38.0% revenue growth vs IIIV's -7.3%
- Beta 0.71 vs ICHR's 3.93
ACMR is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- 30.7% 10Y total return vs MKSI's 7.5%
- 10.4% margin vs ICHR's -5.3%
ICHR ranks third and is worth considering specifically for momentum.
- +329.1% vs IIIV's -13.8%
IIIV is the clearest fit if your priority is value.
- Lower P/E (20.3x vs 30.4x)
MKSI is the clearest fit if your priority is income & stability and defensive.
- Dividend streak 0 yrs, beta 2.64, yield 0.3%
- Beta 2.64, yield 0.3%, current ratio 2.71x
- 0.3% yield, vs ACMR's 0.2%, (3 stocks pay no dividend)
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 38.0% revenue growth vs IIIV's -7.3% | |
| Value | Lower P/E (20.3x vs 30.4x) | |
| Quality / Margins | 10.4% margin vs ICHR's -5.3% | |
| Stability / Safety | Beta 0.71 vs ICHR's 3.93 | |
| Dividends | 0.3% yield, vs ACMR's 0.2%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +329.1% vs IIIV's -13.8% | |
| Efficiency (ROA) | 5.3% ROA vs ICHR's -5.2%, ROIC 15.2% vs -3.9% |
NYAX vs ACMR vs ICHR vs IIIV vs MKSI — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
NYAX vs ACMR vs ICHR vs IIIV vs MKSI — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
IIIV leads in 1 of 6 categories
NYAX leads 1 • ACMR leads 1 • ICHR leads 0 • MKSI leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — NYAX and MKSI each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MKSI is the larger business by revenue, generating $4.1B annually — 18.3x IIIV's $223M. ACMR is the more profitable business, keeping 10.4% of every revenue dollar as net income compared to ICHR's -5.3%. On growth, NYAX holds the edge at +37.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $404M | $901M | $959M | $223M | $4.1B |
| EBITDAEarnings before interest/tax | $65M | $126M | -$11M | $31M | $945M |
| Net IncomeAfter-tax profit | $36M | $94M | -$51M | $16M | $327M |
| Free Cash FlowCash after capex | $32M | -$69M | -$17M | $10M | $401M |
| Gross MarginGross profit ÷ Revenue | +46.3% | +44.4% | +11.3% | +60.4% | +45.2% |
| Operating MarginEBIT ÷ Revenue | +9.7% | +12.1% | -3.8% | +0.8% | +14.8% |
| Net MarginNet income ÷ Revenue | +8.9% | +10.4% | -5.3% | +7.3% | +8.0% |
| FCF MarginFCF ÷ Revenue | +7.8% | -7.6% | -1.7% | +4.7% | +9.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +37.0% | +9.4% | +4.7% | -14.6% | +15.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +7.0% | -76.1% | +46.2% | -78.0% | +53.2% |
Valuation Metrics
IIIV leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 40.9x trailing earnings, IIIV trades at a 42% valuation discount to NYAX's 70.9x P/E. On an enterprise value basis, IIIV's 14.0x EV/EBITDA is more attractive than NYAX's 45.3x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $2.7B | $3.9B | $2.5B | $506M | $20.2B |
| Enterprise ValueMkt cap + debt − cash | $2.6B | $3.5B | $2.6B | $447M | $24.3B |
| Trailing P/EPrice ÷ TTM EPS | 70.93x | 43.21x | -46.25x | 40.91x | 68.83x |
| Forward P/EPrice ÷ next-FY EPS est. | 81.48x | 29.68x | 62.25x | 20.30x | 30.36x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.22x | — | — | — |
| EV / EBITDAEnterprise value multiple | 45.28x | 27.49x | — | 14.02x | 26.70x |
| Price / SalesMarket cap ÷ Revenue | 6.17x | 4.35x | 2.61x | 2.37x | 5.15x |
| Price / BookPrice ÷ Book value/share | 11.79x | 2.06x | 3.67x | 1.51x | 7.49x |
| Price / FCFMarket cap ÷ FCF | 37.75x | — | — | 134.87x | 40.74x |
Profitability & Efficiency
NYAX leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
NYAX delivers a 17.5% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-8 for ICHR. IIIV carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to MKSI's 1.73x. On the Piotroski fundamental quality scale (0–9), MKSI scores 6/9 vs ACMR's 2/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +17.5% | +6.1% | -7.5% | +3.2% | +12.2% |
| ROA (TTM)Return on assets | +5.3% | +3.9% | -5.2% | +2.6% | +3.7% |
| ROICReturn on invested capital | +15.2% | +7.0% | -3.9% | +0.6% | +6.5% |
| ROCEReturn on capital employed | +7.5% | +6.6% | -4.7% | +0.7% | +7.2% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 2 | 3 | 5 | 6 |
| Debt / EquityFinancial leverage | 1.46x | 0.16x | 0.28x | 0.01x | 1.73x |
| Net DebtTotal debt minus cash | -$74M | -$463M | $87M | -$59M | $4.0B |
| Cash & Equiv.Liquid assets | $412M | $766M | $98M | $67M | $675M |
| Total DebtShort + long-term debt | $338M | $303M | $186M | $8M | $4.7B |
| Interest CoverageEBIT ÷ Interest expense | 3.22x | 20.44x | -5.97x | 5.21x | 2.84x |
Total Returns (Dividends Reinvested)
ACMR leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NYAX five years ago would be worth $25,895 today (with dividends reinvested), compared to $7,236 for IIIV. Over the past 12 months, ICHR leads with a +329.1% total return vs IIIV's -13.8%. The 3-year compound annual growth rate (CAGR) favors ACMR at 80.5% vs IIIV's -0.8% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +39.3% | +31.9% | +249.0% | -9.3% | +78.8% |
| 1-Year ReturnPast 12 months | +73.9% | +195.6% | +329.1% | -13.8% | +306.1% |
| 3-Year ReturnCumulative with dividends | +290.7% | +487.9% | +151.1% | -2.5% | +266.0% |
| 5-Year ReturnCumulative with dividends | +158.9% | +133.4% | +28.9% | -27.6% | +66.5% |
| 10-Year ReturnCumulative with dividends | +158.9% | +3065.8% | +629.1% | +24.9% | +750.6% |
| CAGR (3Y)Annualised 3-year return | +57.5% | +80.5% | +35.9% | -0.8% | +54.1% |
Risk & Volatility
Evenly matched — NYAX and ICHR each lead in 1 of 2 comparable metrics.
Risk & Volatility
NYAX is the less volatile stock with a 0.71 beta — it tends to amplify market swings less than ICHR's 3.93 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ICHR currently trades 97.7% from its 52-week high vs IIIV's 67.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.71x | 3.24x | 3.93x | 0.92x | 2.64x |
| 52-Week HighHighest price in past year | $74.83 | $71.65 | $72.87 | $33.97 | $326.83 |
| 52-Week LowLowest price in past year | $37.95 | $19.26 | $13.12 | $19.89 | $71.49 |
| % of 52W HighCurrent price vs 52-week peak | +96.7% | +82.6% | +97.7% | +67.4% | +92.0% |
| RSI (14)Momentum oscillator 0–100 | 74.3 | 60.7 | 66.9 | 47.8 | 65.3 |
| Avg Volume (50D)Average daily shares traded | 21K | 1.2M | 795K | 292K | 1.2M |
Analyst Outlook
Evenly matched — ACMR and MKSI each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: NYAX as "Buy", ACMR as "Buy", ICHR as "Buy", IIIV as "Buy", MKSI as "Buy". Consensus price targets imply 26.6% upside for IIIV (target: $29) vs -33.7% for NYAX (target: $48). For income investors, MKSI offers the higher dividend yield at 0.29% vs ACMR's 0.19%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $48.00 | $40.00 | $49.80 | $29.00 | $272.86 |
| # AnalystsCovering analysts | 6 | 10 | 14 | 14 | 29 |
| Dividend YieldAnnual dividend ÷ price | — | +0.2% | — | — | +0.3% |
| Dividend StreakConsecutive years of raises | — | 3 | 1 | — | 0 |
| Dividend / ShareAnnual DPS | — | $0.11 | — | — | $0.87 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.2% | 0.0% | +7.4% | +0.2% |
IIIV leads in 1 of 6 categories (Valuation Metrics). NYAX leads in 1 (Profitability & Efficiency). 3 tied.
NYAX vs ACMR vs ICHR vs IIIV vs MKSI: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is NYAX or ACMR or ICHR or IIIV or MKSI a better buy right now?
For growth investors, Nayax Ltd.
(NYAX) is the stronger pick with 38. 0% revenue growth year-over-year, versus -7. 3% for i3 Verticals, Inc. (IIIV). i3 Verticals, Inc. (IIIV) offers the better valuation at 40. 9x trailing P/E (20. 3x forward), making it the more compelling value choice. Analysts rate Nayax Ltd. (NYAX) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — NYAX or ACMR or ICHR or IIIV or MKSI?
On trailing P/E, i3 Verticals, Inc.
(IIIV) is the cheapest at 40. 9x versus Nayax Ltd. at 70. 9x. On forward P/E, i3 Verticals, Inc. is actually cheaper at 20. 3x.
03Which is the better long-term investment — NYAX or ACMR or ICHR or IIIV or MKSI?
Over the past 5 years, Nayax Ltd.
(NYAX) delivered a total return of +158. 9%, compared to -27. 6% for i3 Verticals, Inc. (IIIV). Over 10 years, the gap is even starker: ACMR returned +30. 7% versus IIIV's +24. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — NYAX or ACMR or ICHR or IIIV or MKSI?
By beta (market sensitivity over 5 years), Nayax Ltd.
(NYAX) is the lower-risk stock at 0. 71β versus Ichor Holdings, Ltd. 's 3. 93β — meaning ICHR is approximately 449% more volatile than NYAX relative to the S&P 500. On balance sheet safety, i3 Verticals, Inc. (IIIV) carries a lower debt/equity ratio of 1% versus 173% for MKS Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — NYAX or ACMR or ICHR or IIIV or MKSI?
By revenue growth (latest reported year), Nayax Ltd.
(NYAX) is pulling ahead at 38. 0% versus -7. 3% for i3 Verticals, Inc. (IIIV). On earnings-per-share growth, the picture is similar: Nayax Ltd. grew EPS 737. 5% year-over-year, compared to -140. 6% for Ichor Holdings, Ltd.. Over a 3-year CAGR, NYAX leads at 35. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — NYAX or ACMR or ICHR or IIIV or MKSI?
ACM Research, Inc.
(ACMR) is the more profitable company, earning 10. 4% net margin versus -5. 6% for Ichor Holdings, Ltd. — meaning it keeps 10. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MKSI leads at 14. 4% versus -4. 1% for ICHR. At the gross margin level — before operating expenses — IIIV leads at 55. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is NYAX or ACMR or ICHR or IIIV or MKSI more undervalued right now?
On forward earnings alone, i3 Verticals, Inc.
(IIIV) trades at 20. 3x forward P/E versus 81. 5x for Nayax Ltd. — 61. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IIIV: 26. 6% to $29. 00.
08Which pays a better dividend — NYAX or ACMR or ICHR or IIIV or MKSI?
In this comparison, MKSI (0.
3% yield), ACMR (0. 2% yield) pay a dividend. NYAX, ICHR, IIIV do not pay a meaningful dividend and should not be held primarily for income.
09Is NYAX or ACMR or ICHR or IIIV or MKSI better for a retirement portfolio?
For long-horizon retirement investors, Nayax Ltd.
(NYAX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 71), +158. 9% 10Y return). ACM Research, Inc. (ACMR) carries a higher beta of 3. 24 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NYAX: +158. 9%, ACMR: +30. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between NYAX and ACMR and ICHR and IIIV and MKSI?
Both stocks operate in the Technology sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: NYAX is a small-cap high-growth stock; ACMR is a small-cap high-growth stock; ICHR is a small-cap quality compounder stock; IIIV is a small-cap quality compounder stock; MKSI is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.